Filing Flows › LifeStance Health Group (LFST) › Guidance history
LifeStance Health Group (LFST) guidance history: what it guided and what it reported
LifeStance Health Group gave guidance in 12 earnings releases on file since Feb 28, 2024. Of 9 guided periods since reported, it met or beat its own guidance 9 times (100%). Revenue: 9 of 9, on average +2.4% against the guided midpoint. Its releases raised guidance 8 times and lowered it 0 times.
Revenue
Met or beat 9 of 9 periods (4 above, 5 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $446M–$466M (Nov 5, 2026) | — | to be reported | — |
| Q3 2026 | $420M–$440M (Aug 6, 2026) | $456M | above the range | +6.0% |
| Q2 2026 | $405M–$425M (May 7, 2026) | $435M | above the range | +4.9% |
| Q1 2026 | $380M–$400M (Feb 25, 2026) | $403M | above the range | +3.5% |
| FY2026 | $1.6B–$1.7B (Feb 25, 2026) → raised $1.6B–$1.7B (May 7, 2026) → raised $1.7B–$1.7B (Aug 6, 2026) → raised $1.7B–$1.8B (Nov 5, 2026) | — | to be reported | — |
| Q4 2025 | $368M–$388M (Nov 6, 2025) | $382M | within the range | +1.1% |
| FY2025 | $1.4B–$1.4B (Feb 27, 2025) → reaffirmed $1.4B–$1.4B (May 7, 2025) → reaffirmed $1.4B–$1.4B (Aug 7, 2025) → reaffirmed $1.4B–$1.4B (Nov 6, 2025) | $1.4B | within the range | +0.3% |
| Q3 2025 | $345M–$365M (Aug 7, 2025) | $364M | within the range | +2.5% |
| Q2 2025 | $332M–$352M (May 7, 2025) | $345M | within the range | +1.0% |
| Q1 2025 | $320M–$340M (Feb 27, 2025) | $333M | within the range | +0.9% |
Net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $9.7M (Feb 25, 2026) | — | to be reported | — |
Free cash flow
The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $110M (Feb 25, 2026) | — | to be reported | — |
| FY2025 | $85.7M (Feb 27, 2025) | $110M (GAAP) | not judged | — |
Adjusted EBITDA
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $56.0M–$64.0M (Nov 5, 2026) | — | to be reported | — |
| Q3 2026 | $49.0M–$59.0M (Aug 6, 2026) | — | — | — |
| Q2 2026 | $50.0M–$60.0M (May 7, 2026) | — | — | — |
| Q1 2026 | $39.0M–$45.0M (Feb 25, 2026) | — | — | — |
| FY2026 | $158M (Feb 25, 2026) → raised $200M–$220M (May 7, 2026) → raised $215M–$235M (Aug 6, 2026) → raised $242M–$250M (Nov 5, 2026) | — | to be reported | — |
| Q4 2025 | $37.0M–$43.0M (Nov 6, 2025) | — | — | — |
| Q3 2025 | $33.0M–$39.0M (Aug 7, 2025) | — | — | — |
| Q2 2025 | $28.0M–$34.0M (May 7, 2025) | — | — | — |
| Q1 2025 | $27.0M–$33.0M (Feb 27, 2025) | — | — | — |
| FY2025 | $120M (Feb 27, 2025) → raised $130M–$150M (May 7, 2025) → raised $140M–$150M (Aug 7, 2025) → raised $146M–$152M (Nov 6, 2025) | — | — | — |
The latest quarter
LifeStance Health Group, Q3 2026: revenue $456M (+25% year over year), operating margin 7.3%, net earnings $22.4M, operating cash flow $37.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does LifeStance Health Group beat its guidance?
LifeStance Health Group gave guidance in 12 earnings releases on file since Feb 28, 2024. Of 9 guided periods since reported, it met or beat its own guidance 9 times (100%). Revenue: 9 of 9, on average +2.4% against the guided midpoint.
How often does LifeStance Health Group raise guidance?
Its earnings releases raised guidance 8 times and lowered it 0 times since Feb 28, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.